Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Study of Human Lymphocyte Antigen Peptides Reveals New Possible Lung Cancer Treatments

Lung Cancer
A team of researchers from Sheba and the Technion – Israel Institute of Technology studied proteins found in the lung fluid of cancer patients that may be the basis for new treatment and diagnosis techniques.

Headed by Dr. Michael Peled, researcher and attending physician at Sheba’s Institute for Pulmonary Medicine, and Prof. Arie Admon of the Technion – Israel Institute of Technology, the study involved isolating and analyzing peptides (a short chain of amino acids) found in lung fluid, proving that human lymphocyte (a type of white blood cell) antigen peptides can serve as biomarkers for tumor diagnosis, and also store information that helps detect certain types of lung cancer.  

The human lymphocyte antigen system, or HLA, is the part of the immune system used to encode molecules found on the cell’s surface that are specialized to present peptides to the T-cell receptor (TCR) on T-cells, which in turn fight unwanted cells in the body. According to Prof. Admon, “These antigens could be used to stimulate the immune system so that it attacks the tumor.” 

HLA molecules often carry antigens that originate in and around cancerous tumors. As lung cancer often results in fluid buildup in the lungs, these HLA peptides collect in the lung fluid (pleural effusion). Using the methodology they established for the study, researchers can harvest HLA molecules, isolate antigens from the lung fluid and apply them for a variety of purposes.

Lung cancer is the leading cause of global cancer deaths each year, with just a 19 percent 5-year survival rate. In its early stages, lung cancer is treated with surgery, radiotherapy (radiation), and chemotherapy. However, once the cancer has advanced, these treatments tend to be less effective, and oncologists look to immunotherapy or targeted therapy to slow its spread.

Immunotherapy uses the immune system – whether by boosting its operation or manipulating its activity – to attack cancer cells. The new peer-reviewed research study, published in the  Journal for Immunotherapy in Cancer (JITC), suggests that human lymphocyte antigen (HLA) peptides can be used to develop new immunotherapies for lung cancer. 

“We can detect the peptides, and theoretically, they could be used as a new way to diagnose cancer and to create a cancer-fighting vaccine for specific patients,” said Dr. Peled.

The researchers hope their study will promote the development of advanced-stage lung cancer treatments and expedite the diagnostic process, ultimately improving the prognosis for patients across the globe. 

Breakthrough Research
News Jun 05.
Breakthrough Research Provides Pancreatic Cancer Patients with New Hope
Pancreatic cancer is a significant cause of cancer-related death, standing at fourth place globally. It is also the twelfth most common cancer type worldwide, with…
Read More
Sheba Study in collaboration with other medical institutions found an effective way of treatment, a type of cure for hemophilia.
News Jun 05.
Groundbreaking Sheba Study Indicates: New Gene Therapy Offers Rapid Cure for Hemophilia 
Hemophilia is a bleeding disorder that stems from a genetic mutation or alteration in the genes that encode clotting factor proteins, which are necessary for…
Read More
Sheba and Mayo Clinic merge Data-Sharing Network
News May 18.
Sheba and Mayo Clinic Partner to Transform Patient Care Through an Innovative Data-Sharing Network
Sheba Medical Center has joined the Mayo Clinic Platform Connect, a global data-sharing network that aims to revolutionize healthcare. The groundbreaking platform provides a safe,…
Read More